Patent and Technology License Agreements (Details) - USD ($) |
1 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Sep. 30, 2021 |
Jan. 31, 2023 |
Jun. 30, 2022 |
Jan. 31, 2022 |
Jun. 30, 2021 |
Mar. 31, 2023 |
|
Patent and Technology License Agreements (Details) [Line Items] | ||||||
Maintenance fee | $ 75,000 | $ 90,000 | $ 60,000 | $ 90,000 | ||
Royalty payment | $ 100,000 | |||||
Increasing annual royalties | 25,000 | |||||
Maximum aggregate annual royalties | 150,000 | |||||
Payable amount to NAT | 1,100,000 | |||||
Milestone payments | $ 2,100,000 | |||||
Agreement expiration date | Jan. 02, 2034 | |||||
Developmental milestones payment | $ 51,000,000 | |||||
Revenue percentage | 50.00% | |||||
License agreement development, description | Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a biologics license application (“BLA”) for I/ONTAK. | |||||
Extension fee | $ 10,000,000 | |||||
Minimum [Member] | ||||||
Patent and Technology License Agreements (Details) [Line Items] | ||||||
Maintenance fee | 15,000 | |||||
Royalty payment | 100,000 | |||||
Maximum [Member] | ||||||
Patent and Technology License Agreements (Details) [Line Items] | ||||||
Maintenance fee | 90,000 | |||||
Royalty payment | $ 25,000 | |||||
Novellus Inc [Member] | ||||||
Patent and Technology License Agreements (Details) [Line Items] | ||||||
Research and development expense | $ 5,000,000 | |||||
Outstanding equity | 25.00% | |||||
Percentage of outstanding equity | 75.00% | |||||
Percentage of ownership additional shares | 25.00% |